XML 91 R53.htm IDEA: XBRL DOCUMENT v3.7.0.1
- Condensed Consolidated Statement of Operations (Details) - USD ($)
$ / shares in Units, shares in Millions, $ in Millions
3 Months Ended 6 Months Ended 12 Months Ended
Dec. 31, 2016
Oct. 01, 2016
[2]
Jul. 02, 2016
[3]
Apr. 02, 2016
[4]
Dec. 31, 2015
Sep. 26, 2015
[6]
Jun. 27, 2015
Mar. 28, 2015
[8]
Dec. 27, 2014
Sep. 27, 2014
Dec. 31, 2015
Dec. 27, 2014
Dec. 31, 2016
Jun. 27, 2015
Jun. 28, 2014
Error Corrections and Prior Period Adjustments Restatement [Line Items]                              
Non-current deferred income taxes $ 72.1       $ 71.4   $ 50.1       $ 71.4   $ 72.1 $ 50.1 $ 23.6
Non-current deferred income taxes 389.9       1,372.7   1,514.3       1,372.7   389.9 1,514.3 732.6
Net sales 1,331.2 [1] $ 1,261.6 $ 1,340.5 $ 1,347.3 1,359.1 [5] $ 1,273.1 1,415.2 [7] $ 967.2 $ 985.1 [9] $ 859.6 2,632.2 $ 1,844.7 5,280.6 4,227.1 3,914.1
Cost of sales                     1,553.3 1,170.9 3,228.8 2,582.9 2,462.0
Gross profit 487.7 [1] 484.5 546.5 533.1 543.7 [5] 535.2 601.0 [7] 369.4 369.7 [9] 304.1 1,078.9 673.8 2,051.8 1,644.2 1,452.1
Operating expenses                              
Distribution                     47.9 29.2 88.3 67.7 55.3
Research and development                     88.2 89.8 184.0 187.8 152.5
Selling                     325.9 95.3 665.0 319.0 208.6
Administration                     306.8 165.6 452.2 385.3 411.3
Impairment charges (credits)                     215.6 0.0 2,631.0 6.8 6.0
Restructuring charges         24.7           26.9 4.2 31.0 5.1 47.0
Total operating expenses                     1,011.3 384.1 4,051.5 971.7 880.7
Operating income (loss)                     67.6 289.7 (1,999.7) 672.5 571.4
Royalty rights - change in fair value (1,115.6) [1] 377.4 910.8 204.4 (116.6) [5] (173.8) 69.2 [7] (100.8) 105.8 [9] (58.9) (57.3) (46.9) 2,608.2 (78.5) (26.6)
Interest expense, net                     89.9 56.7 216.6 146.0 103.5
Other expense, net                     25.2 60.3 22.7 334.2 25.1
Loss on extinguishment of debt                 9.6   0.9 9.6 1.1 10.5 165.8
Income (loss) before income taxes                     8.9 210.0 (4,848.3) 260.3 303.6
Income tax expense (benefit)                     (33.6) 29.4 (835.5) 124.2 70.8
Net income (loss) $ (1,359.1) [1] $ (1,590.2) $ (534.3) $ (529.2) $ (218.4) [5] $ 260.9 $ (22.2) [7] $ (22.2) $ 151.1 [9] $ 29.4 $ 42.5 $ 180.6 $ (4,012.8) $ 136.1 $ 232.8
Earnings Per Share [Abstract]                              
Basic income (loss) per share (in dollars per share) $ (9.48) [1],[10] $ (11.10) [10] $ (3.73) [10] $ (3.70) [10] $ (1.51) [5],[10] $ 1.78 [10] $ (0.15) [7],[10] $ (0.16) [10] $ 1.11 [9],[10] $ 0.22 [10] $ 0.29 $ 1.34 $ (28.01) $ 0.97 $ 2.02
Diluted income (loss) per share (in dollars per share) $ (9.48) [1],[10] $ (11.10) [10] $ (3.73) [10] $ (3.70) [10] $ (1.51) [5],[10] $ 1.78 [10] $ (0.15) [7],[10] $ (0.16) [10] $ 1.10 [9],[10] $ 0.22 [10] $ 0.29 $ 1.34 $ (28.01) $ 0.97 $ 2.01
Weighted-average shares outstanding                              
Basic (in shares) 143.4 [1] 143.3 143.2 143.2 144.9 [5] 146.3 146.3 [7] 140.8 136.3 [9] 133.9 145.6 135.1 143.3 139.3 115.1
Diluted (in shares) 143.4 [1] 143.3 143.2 143.2 144.9 [5] 146.9 146.3 [7] 140.8 136.8 [9] 134.4 146.1 135.6 143.3 139.8 115.6
Previously Reported                              
Error Corrections and Prior Period Adjustments Restatement [Line Items]                              
Non-current deferred income taxes         $ 54.6   $ 39.6       $ 54.6     $ 39.6 $ 23.6
Non-current deferred income taxes         1,563.7   1,745.1       1,563.7     1,745.1 727.9
Net sales                     2,769.5     4,603.9 4,060.8
Cost of sales                     1,661.4     2,891.4 2,613.1
Gross profit                     1,108.1     1,712.5 1,447.7
Operating expenses                              
Distribution                     47.9     67.7 55.3
Research and development                     88.2     187.8 158.5
Selling                     325.9     319.0 208.6
Administration                     309.1     385.2 411.3
Impairment charges (credits)                     215.6     0.0 0.0
Restructuring charges                     26.9     5.1 47.0
Total operating expenses                     1,013.6     964.8 880.7
Operating income (loss)                     94.5     747.7 567.0
Royalty rights - change in fair value                     0.0     0.0 0.0
Interest expense, net                     89.9     146.0 103.5
Other expense, net                     26.9     343.2 25.1
Loss on extinguishment of debt                     0.9     10.5 165.8
Income (loss) before income taxes                     (23.2)     248.0 272.6
Income tax expense (benefit)                     (28.8)     120.0 67.3
Net income (loss)                     $ 5.6     $ 128.0 $ 205.3
Earnings Per Share [Abstract]                              
Basic income (loss) per share (in dollars per share)                     $ 0.04     $ 0.92 $ 1.78
Diluted income (loss) per share (in dollars per share)                     $ 0.04     $ 0.92 $ 1.77
Weighted-average shares outstanding                              
Basic (in shares)                     145.6     139.3 115.1
Diluted (in shares)                     146.1     139.8 115.6
BCH Deferred Tax Matters Misstatement | Adjustments                              
Error Corrections and Prior Period Adjustments Restatement [Line Items]                              
Non-current deferred income taxes         272.2   268.9       $ 272.2     $ 268.9  
Non-current deferred income taxes         65.4   4.0       65.4     4.0  
Tysabri® | Adjustments                              
Error Corrections and Prior Period Adjustments Restatement [Line Items]                              
Non-current deferred income taxes         0.0   0.0       0.0     0.0 $ 0.0
Non-current deferred income taxes         12.2   7.9       12.2     7.9 4.1
Net sales                     (166.4)     (338.5) (146.7)
Cost of sales                     (145.0)     (290.1) (152.8)
Gross profit                     (21.4)     (48.4) 6.1
Operating expenses                              
Distribution                     0.0     0.0 0.0
Research and development                     0.0     0.0 0.0
Selling                     0.0     0.0 0.0
Administration                     0.0     0.0 0.0
Impairment charges (credits)                     0.0     0.0 0.0
Restructuring charges                     0.0     0.0 0.0
Total operating expenses                     0.0     0.0 0.0
Operating income (loss)                     (21.4)     (48.4) 6.1
Royalty rights - change in fair value                     (57.3)     (78.5) (26.6)
Interest expense, net                     0.0     0.0 0.0
Other expense, net                     0.9     0.0 0.0
Loss on extinguishment of debt                     0.0     0.0 0.0
Income (loss) before income taxes                     35.0     30.1 32.7
Income tax expense (benefit)                     4.4     3.8 4.1
Net income (loss)                     $ 30.6     $ 26.3 $ 28.6
Earnings Per Share [Abstract]                              
Basic income (loss) per share (in dollars per share)                     $ 0.21     $ 0.18 $ 0.25
Diluted income (loss) per share (in dollars per share)                     $ 0.21     $ 0.18 $ 0.25
Other | Adjustments                              
Error Corrections and Prior Period Adjustments Restatement [Line Items]                              
Non-current deferred income taxes         16.8   10.5       $ 16.8     $ 10.5 $ 0.0
Non-current deferred income taxes         $ (203.2)   $ (238.7)       (203.2)     (238.7) 0.6
Net sales                     29.1     (38.3) 0.0
Cost of sales                     36.9     (18.4) 1.7
Gross profit                     (7.8)     (19.9) (1.7)
Operating expenses                              
Distribution                     0.0     0.0 0.0
Research and development                     0.0     0.0 (6.0)
Selling                     0.0     0.0 0.0
Administration                     (2.3)     0.1 0.0
Impairment charges (credits)                     0.0     6.8 6.0
Restructuring charges                     0.0     0.0 0.0
Total operating expenses                     (2.3)     6.9 0.0
Operating income (loss)                     (5.5)     (26.8) (1.7)
Royalty rights - change in fair value                     0.0     0.0 0.0
Interest expense, net                     0.0     0.0 0.0
Other expense, net                     (2.6)     (9.0) 0.0
Loss on extinguishment of debt                     0.0     0.0 0.0
Income (loss) before income taxes                     (2.9)     (17.8) (1.7)
Income tax expense (benefit)                     (9.2)     0.4 (0.6)
Net income (loss)                     $ 6.3     $ (18.2) $ (1.1)
Earnings Per Share [Abstract]                              
Basic income (loss) per share (in dollars per share)                     $ 0.04     $ (0.13) $ (0.01)
Diluted income (loss) per share (in dollars per share)                     $ 0.04     $ (0.13) $ (0.01)
[1] ncludes intangible asset impairment charges of $378.6 million, goodwill impairment charges of $224.1 million, and a reduction in held-for-sale impairment charges of $4.5 million. September 26, 2015 (2) December 31, 2015 (3)Six Months Ended December 31, 2015Restated RestatedNet sales$1,273.1 $1,359.1Gross profit$535.2 $543.7Tysabri® royalty stream - change in fair value$(173.8) $116.6Net income (loss)$260.9 $(218.4)Income (loss) per share(1): Basic$1.78 $(1.51)Diluted$1.78 $(1.51)Weighted-average shares outstanding Basic146.3 144.9Diluted146.9 144.9
[2] Includes intangible asset impairment charges of $866.6 million, goodwill impairment charges of $737.9 million, and held-for-sale impairment charges of $10.2 million.
[3] Includes held-for-sale impairment charges of $10.5 million and change in fair market value on royalty rights of $910.8 million.
[4] Includes an intangible asset impairment charges of $273.3 million, and a goodwill impairment charge of $130.5 million.
[5] Includes an intangible asset impairment charge of $185.1 million, Mylan defense-related fees of $71.3 million, an impairment charge on our India API held for sale assets of $29.0 million, restructuring charges of $24.7 million, and an investment impairment charge of $10.7 million.
[6] Includes Mylan defense-related fees of $15.6 million.
[7] (4) Includes acquisition costs of $18.5 million, an initial payment made in connection with an R&D agreement of $18.0 million, an inventory step up related to the Omega acquisition totaling $15.6 million, and $13.4 million of Mylan defense-related fees.
[8] Includes losses on derivatives associated with the Omega acquisition of $258.2 million and Omega financing fees of $18.6 million.
[9] Includes losses on derivatives associated with the Omega acquisition of $64.7 million, Omega transaction expenses of $17.8 million, an R&D payment made in connection with a collaborative agreement of $10.0 million, a $9.6 million loss on extinguishment of debt, partially offset by income from transfer of rights agreement of $12.5 million.
[10] The sum of individual per share amounts may not equal due to rounding.